红霉素的心脏安全性研究进展  

Research Advances in Cardiac Safety of Erythromycin

作　　者：张燕婷 陈渊[1] 赵伟 ZHANG Yan-ting;CHEN Yuan;ZHAO Wei(Institute of Traditional Chinese Medicine, School of Forestry and Biotechnology, Zhejiang A＆F University, Hang- zhou 311300, China)

机构地区：[1]浙江农林大学林业与生物技术学院中药学科,浙江杭州311300

出　　处：《药物生物技术》2018年第2期166-170,共5页Pharmaceutical Biotechnology

基　　金：浙江农林大学科研发展基金资助项目(No.2013FR032);浙江省基础公益研究计划项目(No.LGF18H280002)

摘　　要：红霉素是一种大环内酯类抗生素,临床应用广泛,但在使用过程中可能会引发较为严重的心脏毒性,主要表现为QT间期延长,尖端扭转型室性心动过速TdP(Torsades de pointes),甚至心脏猝死等。红霉素对心脏hERG(Human ether-a-go-go-related gene)钾通道的抑制作用是引发心脏毒性的重要机制,多种因素会增加红霉素心脏毒性发生的几率。随着红霉素在临床中的广泛使用,其心脏安全性引起广泛关注。文章综述了红霉素心脏安全性方面的研究进展,评估了使用中存在的危险因素,为临床中能够更加合理地使用红霉素提供参考。Erythromycin is a macrolide antibiotic widely used in clinical practice, but it may lead to some serious cardiotoxicity, such as QT interval prolongation,torsades de pointes （TdP） and even sudden cardiac death. The inhibitory effect of Erythromycin on the human ether-a-go-go-related gene （hERG） potassium channel is an important mechanism of cardiotoxicity, and there are many factors that can increase the risk of cardiotoxicity. With the wide spread use of Erythromycin, its cardiac safety has become a hot topic. In this paper, the progress of research in the cardiac safety of Erythromycin is reviewed, and the risk factors in application are evaluated so that Erythromycin can be used more reasonably in clinic.

关 键 词：红霉素 QT间期延长 TDP HERG钾通道 心脏安全性 

分 类 号：R972[医药卫生—药品] R978[医药卫生—药学]